Status: Recruiting
Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
This research study is studying a drug called Paxalisib (GDC-0084) as a possible treatment for primary central nervous system lymphoma (PCNSL)
Participants needed: 25
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Lakshmi Nayak, MDUpdated: Jun 26, 2025Locations: 2
Eligibility criteria
Participants must be able to understand and willing to sign a written informed c... [+25]
Participants unable to undergo MRI brain. [+15]